CelLBxHealth revenue doubles in Q2, but funding risk remains

CelLBxHealth's second-quarter results at a glance

CelLBxHealth reported revenue of £0.4 million for the second quarter of 2026, double the £0.2 million recorded in the first quarter.

The sequential improvement is encouraging, but it needs to be viewed alongside the wider half-year result. Revenue for the six months ended 30 June 2026 was £0.6 million, down from £0.8 million in the comparable period. The business is therefore growing from the first quarter's low base rather than yet demonstrating year-on-year growth.

Metric	H1 2026	H1 2025	Change
Revenue	£0.6 million	£0.8 million	Down 25%
Gross profit	£0.4 million	Not disclosed in the update	—
Gross margin	61%	59%	Up 2 percentage points
Operating loss	£2.7 million	£9.7 million	Loss reduced by £7.0 million
Loss after tax	£2.7 million	£9.3 million	Loss reduced by £6.6 million
Period-end cash	£2.9 million	Not disclosed in the update	—

The gross margin improved to 61% from 59%. More importantly, the operating loss narrowed substantially following the company's restructuring and lower operating cost base.

Why the lower loss matters

CelLBxHealth is still a small, loss-making diagnostics business, so controlling expenditure is central to its investment case.

Management said the annualised operating cash cost base had been reduced to approximately £6.3 million. More than £1.5 million of restructuring cash payments were made during the first half, which means the reported cash movement included costs intended to support a leaner business in future periods.

The reduction in the operating loss from £9.7 million to £2.7 million is therefore meaningful. It suggests that the company has removed a considerable amount of expenditure while continuing to develop commercial relationships.

However, a smaller loss is not the same as self-sufficiency. Revenue remains modest relative to the cost base, and the company expects to remain loss-making before interest, tax, depreciation and amortisation until 2028.

Investors should distinguish between two questions: whether the restructuring has improved the economics of the business, and whether CelLBxHealth has enough capital to reach the point at which those economics become sustainable.

Cash runway remains the central risk

CelLBxHealth ended June with £2.9 million of cash. Management expects a monthly cash burn of between £0.3 million and £0.4 million and said existing resources should provide a runway into the second quarter of 2027.

That guidance offers a reference point, but it is not a guarantee. Cash usage can change if revenue arrives later than expected, customers delay studies, restructuring costs exceed plans or the business chooses to accelerate investment.

At the stated burn rate, £2.9 million represents roughly seven to ten months of expenditure before allowing for incoming revenue, working-capital movements or other cash items. Management's longer runway expectation therefore depends partly on commercial receipts and disciplined spending.

This creates an obvious funding question. Unless revenue and cash collection improve quickly enough, CelLBxHealth may need additional capital before it reaches its 2028 EBITDA objective. A fundraising could strengthen the balance sheet, but it could also dilute existing shareholders if new shares are issued.

The timing of any financing may be as important as the amount. A company negotiating with limited cash generally has fewer options than one raising capital after delivering stronger commercial evidence.

Commercial partnerships are developing

The first half included several pieces of commercial and clinical progress.

CelLBxHealth signed a master services agreement with AstraZeneca. It also continued studies with AdventHealth and announced a collaboration with The Royal Marsden NHS Foundation Trust. The company referred to work involving established diagnostics and life-sciences groups including QIAGEN, Roche, Illumina and Myriad Genetics.

These relationships can help validate the company's technology and broaden its access to potential customers. They may also create future project revenue or support wider adoption if studies produce useful results.

The distinction between a relationship and recognised revenue is important, though. An agreement, pilot or research collaboration does not necessarily become a large recurring contract. Investors need to track whether named partnerships progress into paid work, whether individual projects expand and how quickly the sales pipeline converts into reported revenue.

CelLBxHealth also sublet part of its US premises as it reduced costs. This is consistent with the wider restructuring, although it reinforces the need to assess how the company balances lower spending with the commercial resources required to grow.

What does the revenue outlook imply?

Management expects full-year 2026 revenue of at least £2.1 million, representing growth of more than 50%. It also reported a weighted commercial pipeline of £3.5 million.

The £2.1 million target implies a substantial second-half weighting. With £0.6 million recognised in the first six months, the company needs at least £1.5 million in the second half to meet the stated minimum. That would be two and a half times first-half revenue.

This is possible for a small project-led company, where the timing of a limited number of contracts can materially affect a reporting period. It also makes execution risk unusually visible. Delays to one or two projects could have a large effect on both reported growth and the cash runway.

A weighted pipeline is not equivalent to contracted revenue. Weighting normally applies a probability to opportunities at different stages, but the result can still change as customer decisions and project schedules develop.

Future updates should therefore be judged on conversion into recognised revenue and cash, rather than the headline size of the pipeline alone.

Leadership changed during a sensitive period

Chief executive Peter Collins left the company on 6 July 2026. Executive chair Jan Groen is leading the business while a permanent successor is recruited.

Management transitions always create some uncertainty, particularly when a company is simultaneously restructuring, pursuing commercial partnerships and managing a limited cash runway.

The board will need to maintain continuity with customers and employees while choosing a leader capable of turning scientific and clinical relationships into repeatable commercial growth. Investors should watch for clarity on the recruitment process, any change in strategy and whether the 2026 revenue outlook remains intact under the interim arrangement.

What should investors watch next?

The second-quarter revenue improvement and sharp reduction in losses show progress. The higher gross margin and lower annualised cost base also give the company a better operating platform than the prior-year loss figures suggest.

The investment case is nevertheless still dominated by execution and financing risk. First-half revenue declined year on year, the full-year target requires a much stronger second half, and the current cash balance does not remove the possibility of another fundraising.

The most useful indicators in the next update will be:

• Revenue recognised from existing partnerships and studies
• Conversion of the £3.5 million weighted pipeline
• Actual monthly cash burn after restructuring payments subside
• The period-end cash balance and any financing plans
• Progress towards the minimum £2.1 million full-year revenue target
• Appointment of a permanent chief executive

CelLBxHealth has made the business less costly and reported a better second quarter. It now needs to show that commercial growth can arrive quickly enough to extend the runway and reduce dependence on external funding.